EC Number |
Activating Compound |
Reference |
---|
2.7.1.36 | arsenate |
hyperbolic activation curve, 13% activation at 25 mM, 87% activation at 500 mM |
641436 |
2.7.1.36 | atorvastatin |
besides increases in mRNA level of HMG CoA reductase, treatment increases hepatic mRNA levels of both mevalonate kinase and cob(I)alamin adenosyltransferase |
690694 |
2.7.1.36 | ATP4- |
most effective activator, maximal activation at 8 mM |
641436 |
2.7.1.36 | cysteine |
not required for activity |
641443 |
2.7.1.36 | cysteine |
or to a lesser extent other SH-compounds required |
641431 |
2.7.1.36 | iodoacetamide |
10 mM, 20% activation |
641438 |
2.7.1.36 | phosphate |
50% activation at 100 mM |
641436 |
2.7.1.36 | phosphate |
required for activity |
641431 |
2.7.1.36 | testosterone |
treatment of meibomian gland stimulates a significant increase in the mRNA levels of mevalonate kinase, phosphomevalonate kinase, mevalonate diphosphate decarboxylase, isopentenyl diphosphate isomerase, geranylgeranyl diphosphate synthase, squalene epoxidase, lanosterol synthase, lanosterol demethylase, and DELTA7-sterol reductase |
691939 |
2.7.1.36 | UTP |
stimulation of ATP utilization |
641430 |